TEIKOKU PHARMA
LIVE

Serial Number

79123060

Owner

Teikoku Pharma UK Limited

Attorney

Bret E. Field

Filing Date

Sep 20, 2012

Add to watchlist:

No watchlists yet
View on USPTO

TEIKOKU PHARMA Trademark

Serial Number: 79123060 • Registration: 4416497

TEIKOKU PHARMA is a trademark filed by Teikoku Pharma UK Limited on September 20, 2012. The trademark is classified under Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Teikoku Pharma UK Limited

Central House,

Entity Type: 99

Teikoku Pharma USA, Inc. (38 trademarks)

1718 Rigwood Avenue
San Jose, CA 95131

Entity Type: 03

Trademark Details

Filing Date

September 20, 2012

Registration Date

October 15, 2013

Published for Opposition

July 30, 2013

Goods & Services

Pharmaceuticals for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; pharmaceutical preparations, compositions, creams and lotions for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; prescription and over-the-counter pharmaceutical preparations for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; prescription and over-the-counter pharmaceutical preparations, namely, transdermal gel formulations, transdermal cream formulations, oral mucous formulations, transdermal patches, dressings and medical adhesive tapes for use in the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions

[ Cosmetics; cosmetic preparations; adhesives for cosmetic purposes; cosmetic masks; soaps for personal use; perfumery; essential oils; hair lotions ]

Pharmaceutical research and development; pharmaceutical product evaluation, testing and inspection services; providing medical and scientific research information in the field of pharmaceuticals; information, advisory and consultancy services relating to all the aforesaid services

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 28, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 28, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 28, 2024 REAP
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
May 11, 2024 NA75
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
May 11, 2024 C75A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
May 7, 2024 APRE
TEAS SECTION 71 & 15 RECEIVED
Sep 15, 2023 ES75
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Oct 15, 2022 REM4
INTERNATIONAL REGISTRATION RENEWED
Oct 6, 2022 RNWL
PARTIAL INVALIDATION PROCESSED BY THE IB
Oct 17, 2020 INNP
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Sep 5, 2020 INPS
INVALIDATION PROCESSED
Aug 26, 2020 INPC
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Jul 21, 2020 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Nov 21, 2019 NA75
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
Nov 21, 2019 C75P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Nov 21, 2019 APRE
TEAS SECTION 71 & 15 RECEIVED
Oct 14, 2019 ES75
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Oct 15, 2018 REM3
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 9, 2017 TCCA
FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 10, 2014 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Mar 3, 2014 FICS
FINAL DISPOSITION PROCESSED
Mar 3, 2014 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 15, 2014 FICR
REGISTERED-PRINCIPAL REGISTER
Oct 15, 2013 R.PR
PUBLISHED FOR OPPOSITION
Jul 30, 2013 PUBO
NOTICE OF PUBLICATION
Jul 10, 2013 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jun 24, 2013 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 17, 2013 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 30, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 30, 2013 CRFA
ASSIGNED TO LIE
May 22, 2013 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 20, 2013 TROA
CHANGE OF OWNER RECEIVED FROM IB
May 11, 2013 CHLD
REFUSAL PROCESSED BY IB
Feb 27, 2013 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 28, 2013 RFCS
REFUSAL PROCESSED BY MPU
Jan 28, 2013 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 26, 2013 RFCR
NON-FINAL ACTION WRITTEN
Jan 25, 2013 CNRT
ASSIGNED TO EXAMINER
Jan 18, 2013 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 15, 2013 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 9, 2013 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 3, 2013 REPR